vericiguat and Hypertension

vericiguat has been researched along with Hypertension* in 3 studies

Reviews

1 review(s) available for vericiguat and Hypertension

ArticleYear
Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session.
    Current atherosclerosis reports, 2020, 06-18, Volume: 22, Issue:8

    The review highlights selected studies related to cardiovascular disease (CVD) prevention that were presented at the American College of Cardiology 2020 Virtual Scientific Session (ACC.20)/World Cardiology Congress (WCC).. The studies reviewed include clinical trials on the efficacy and safety of alirocumab (Study in Participants with Homozygous Familial Hypercholesterolemia [ODYSSEY HoFH]) and evinacumab in the treatment of homozygous familial hypercholesterolemia (HoFH); Evaluating the Efficacy of E-cigarettes for Smoking Cessation (E3); the use of renal denervation in the treatment of hypertension (SPYRAL HTN-OFF MED PIVOTAL); and the assessment of vericiguat in the treatment of heart failure (A Study of Vericiguat in Participants with Heart Failure with Reduce Ejection Fraction [VICTORIA]). In addition, results from the pooled analysis of phase III trials on inclisiran and secondary analysis examining eicosapentaenoic acid levels and cardiovascular outcomes from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) were included. Finally, we discuss studies examining the use of polygenic risk score with low density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP) on lifetime cardiovascular risk. The studies presented at the ACC.20/WCC represent notable contributions in the field of CVD prevention.

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Child; Cholesterol, LDL; Denervation; Eicosapentaenoic Acid; Electronic Nicotine Delivery Systems; Female; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hyperlipoproteinemia Type II; Hypertension; Kidney; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Smoking Cessation; United States; Young Adult

2020

Other Studies

2 other study(ies) available for vericiguat and Hypertension

ArticleYear
Vericiguat Improves Aortic Wave Reflection Parameters in a New Preclinical Model of Hypertension.
    Circulation. Heart failure, 2022, Volume: 15, Issue:1

    Topics: Animals; Blood Pressure; Disease Models, Animal; Dogs; Heart Failure; Heterocyclic Compounds, 2-Ring; Hypertension; Pyrimidines; Stroke Volume

2022
Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?
    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2021, Volume: 28, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hypertension; Neprilysin; Pyrimidines; Stroke Volume; Tetrazoles; Valsartan

2021